Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial - Wikidata - awgldk - TriplyDB

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

http://www.wikidata.org/entity/Q34248742

about

Antibiotics for secondary prevention of coronary heart disease The Danish National Patient Registry: a review of content, data quality, and research potential Cardiovascular disease and type 2 diabetes in evolutionary perspective: a critical role for helminths?Listen to the data when results are not significant New perspectives of infections in cardiovascular disease Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease Macrolide antibiotics and the risk of cardiac arrhythmias Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury.Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis.Absence of Bacteria on Coronary Angioplasty Balloons from Unselected Patients: Results with Use of a High Sensitivity Polymerase Chain Reaction Assay.Infection and Atherosclerosis Development Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.Toll-like receptors and human disease: lessons from single nucleotide polymorphisms.Toll-like Receptors in the Vascular System: Sensing the Dangers Within.The interaction of bacterial pathogens with platelets.Chlamydophila pneumoniae infection and cardiovascular disease Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs.Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials.Targeting inflammation in cardiovascular diseases. still a neglected field?Novel effects of macrolide antibiotics on cardiovascular diseases.Molecular biology of atherosclerosis.Targeting inflammation: impact on atherothrombosis.Gut Microbiota and Atherosclerosis.Helicobacter pylori infection and atherosclerosis: is there a causal relationship?Early termination of drug trials.Treatment of disorders of hypersomnolence.Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials.Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) T Antibiotics for secondary prevention of coronary heart disease Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial New insights on atherosclerosis: A cross-talk between endocannabinoid systems with gut microbiota

P2860

Q24201388-047FE935-D5E2-4623-AEFE-C509092306B1 Q26775834-ABA57874-71FB-4073-8143-FD6D74A51F1C Q28069923-2E2A76A4-F601-4E67-A599-BB7B9AC27422 Q31141843-B614C3BA-3DD1-4CF6-966F-2E6116D93BCD Q33587960-BE70DD79-AF57-4080-BD8F-E24A747F7035 Q33646625-B2B45224-3C5A-42F7-B9D7-926EA9852FC3 Q33772270-D2719F84-71DE-4DF2-9E2A-82FD2530FB34 Q34027076-7633DBAC-DA09-4AEF-9A27-D77BA92C07FC Q34174166-27111023-7CA8-4C17-8E25-508E05A215D6 Q34389792-2EA81154-E9D7-4338-8E7F-1D1EA20CAE36 Q34510105-8EE8B915-F711-4B31-8D9A-DCFE3BA42DA6 Q35875899-E2CD464C-3CE2-4AB3-B37F-43FE82FE32B9 Q35915081-03C21BA7-2CD0-48DF-B46B-2092F8D0C1C8 Q36342810-90590E0F-8B12-47F6-8D37-46E458A4EB78 Q36382348-5566C0F7-46E3-451E-89A7-461F44817847 Q36453194-894E3D79-394E-4B52-94F7-521B364470B1 Q36482515-7EC39CD4-C779-4F6A-AD8B-A55D5265B9FA Q36783331-89C35474-22E1-4169-957F-8EF018BD6C34 Q36808701-FA8EC38D-89DF-4CEC-BC45-50BEF9E3B5CB Q37098266-1BB3D045-77CE-47B7-B6D8-63E2AABD5AA2 Q37149458-76534E96-710C-4BC9-8B2A-8916273DE235 Q37844575-81D48BB5-F6A1-4041-A396-CA8722DF4EBA Q37925018-F4A3294A-451E-481C-9AE5-CA4EDBFA8EE5 Q37964006-CA33CCD4-685F-4456-909C-56E7C1F434C7 Q38125279-1346AACB-F5A1-4F6E-ACA8-102EE02BD898 Q38170328-24E1B609-F465-4D91-90E9-7C9D0CF0F9A3 Q40079055-AF2CE540-5295-4320-9B66-B5831A9D5615 Q40116049-ADD45C3D-1666-4641-A676-AD92079F8D15 Q42951671-76BD1CB3-2A16-4E45-903F-8643F8115AC3 Q46026424-AEFA28C8-36FA-4F9D-9931-91BAE2170B6E Q46420088-7CD9CBF0-0A86-419B-87FE-AD52919EC675 Q46738236-71F4867C-32CF-41C7-9945-BD39CCA3F1CE Q51778180-2B524CDF-ABDE-4A08-B4C5-14FAC8E8EC05 Q55445795-AAD6D103-235E-49C6-80C5-5D76D7159CF1 Q57389403-CF816652-2539-45BB-9018-78CB208CA6F9 Q57389466-0C866A22-6C62-42BE-BDDB-526585A5F546 Q57389527-698A128B-0A44-4A94-8E20-1E6B3E8636AB Q58040795-BA1D0436-02D4-4F14-80B2-765791853A2A Q58040909-67A2B5D2-ED24-44BF-9B80-F7D0DE7B5777 Q58580826-C9142BE1-D6DA-4440-BCE6-6203B1CF30ED

P2860

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

http://www.wikidata.org/entity/Q34248742

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Randomised placebo controlled ...... heart disease: CLARICOR trial

@ast

Randomised placebo controlled ...... heart disease: CLARICOR trial

@en

Randomised placebo controlled ...... heart disease: CLARICOR trial

@nl

type

label

Randomised placebo controlled ...... heart disease: CLARICOR trial

@ast

Randomised placebo controlled ...... heart disease: CLARICOR trial

@en

Randomised placebo controlled ...... heart disease: CLARICOR trial

@nl

prefLabel

Randomised placebo controlled ...... heart disease: CLARICOR trial

@ast

Randomised placebo controlled ...... heart disease: CLARICOR trial

@en

Randomised placebo controlled ...... heart disease: CLARICOR trial

@nl

P1433

Q34248742-573B0C56-6EBC-4C9D-AFB3-20FEC37398E8

P1476

Q34248742-B3C3F9D6-34D7-4087-ACC2-864ECBD2B4EA

P2093

Q34248742-00542D35-545D-4934-A281-63AFD754B187

Q34248742-06459FAD-2A3A-4162-88AA-08EBC69433B4

Q34248742-116C0C2E-5226-4D9C-A74D-FF8AC46BB096

Q34248742-283FB32E-DD63-47B8-9CF1-CDCA28C743AA

Q34248742-29A8B8C6-03CA-4727-AA59-21E1CB4FD0F6

Q34248742-324B4429-E569-462D-B3BC-668182CBBA91

Q34248742-3598FF06-1796-4231-940A-1E7F5C8E936F

Q34248742-4C2A8A4C-40F8-4D66-A454-00605B51ECCB

Q34248742-4CA127CA-E110-4A4B-AC77-A0B7067BB010

Q34248742-4FBB6C20-4C59-45C9-91F0-CADF7CF03256

P2860

Q34248742-06B93227-A2E1-46EC-ABB0-B77E799114D8

Q34248742-11FFC1CC-F635-4830-867D-720278F1DFC1

Q34248742-24C7E485-A0CB-4AB6-9178-D67ED1B9E931

Q34248742-2995499F-7C77-4D08-A678-AE107F0004BD

Q34248742-3C80A5F9-108B-4518-95CE-3590EF808424

Q34248742-436104E8-0057-4678-88BC-54D60BCC6796

Q34248742-43A305A0-15EE-460A-8E32-8EE0F0204E6A

Q34248742-43E8EF1F-1F14-449C-9BD4-AC118121E6BF

Q34248742-4C26D487-D5D4-44CC-B244-531628E9025A

Q34248742-5E951753-C8D8-414D-A9ED-A3DB311BC1B9

P304

Q34248742-A63A4592-04E0-4AAC-AF4B-42BF297CAD40

P31

Q34248742-7B46BB82-39BE-41D6-8506-3D656DF13AD8

P356

Q34248742-C6973EC5-43AF-426D-92C3-9F12729920FF

P407

Q34248742-0A24EEB9-02EE-4BA1-99FD-122DF20EDFC8

P433

Q34248742-DA4A5FFC-4BDF-4B35-90E3-64A79FD8FBD9

P478

Q34248742-618D15D7-CBFA-4598-A484-92766437DCF5

P50

Q34248742-559774F0-60A7-47BB-B720-37A7B13CD401

P577

Q34248742-0D33ABD1-912F-4004-B3F0-956158932469

P5875

Q34248742-76E1EF8C-6658-40D6-9027-D0B4853111F6

P698

Q34248742-5AEC7270-90DD-4C14-881E-3A3D108D277F

P921

Q34248742-04C61D7D-4BD0-4178-99A9-2E766D13C565

Q34248742-0938513D-AC87-46B7-846B-90CBB224E565

P932

Q34248742-AC4DDF50-E5BF-44B8-93BD-C70FB937DB06

P356

BMJ.38666.653600.55

P1433

P1476

Randomised placebo controlled ...... heart disease: CLARICOR trial

@en

P2093

Bodil Als-Nielsen

http://www.w3.org/2001/XMLSchema#string

CLARICOR Trial Group

http://www.w3.org/2001/XMLSchema#string

Christian M Jespersen

http://www.w3.org/2001/XMLSchema#string

Erik Kjøller

http://www.w3.org/2001/XMLSchema#string

Gorm B Jensen

http://www.w3.org/2001/XMLSchema#string

Hans Jørn Kolmos

http://www.w3.org/2001/XMLSchema#string

Henrik Nielsen

http://www.w3.org/2001/XMLSchema#string

Inga Lind

http://www.w3.org/2001/XMLSchema#string

Jens Kastrup

http://www.w3.org/2001/XMLSchema#string

Jørgen Fischer Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Inflammation and atherosclerosis

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Oral erythromycin and the risk of sudden death from cardiac causes.

Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials.

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT.

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.

Azithromycin for the secondary prevention of coronary events.

P304

22-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.38666.653600.55

http://www.w3.org/2001/XMLSchema#string

P407

P433

7532

http://www.w3.org/2001/XMLSchema#string

P478

332

http://www.w3.org/2001/XMLSchema#string

P50

Christian Gluud

P577

2005-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7430983

http://www.w3.org/2001/XMLSchema#string

P698

16339220

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

1325128

http://www.w3.org/2001/XMLSchema#string